Life Sciences
The pilot study in north-east England will pioneer a personalised medicine approach.
The pair talk about the shift from traditional clinical trials based on drug research to digital innovations.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
The company's technology looks to reduce the burden on pathologists reviewing digital slides, while also serving as a safety net to reduce errors.
Along with the support of a Google Cloud-backed data platform, the partners will work to build and validate digital health programs for early intervention and engagement.
An initial pilot scheme will provide patients with access to local community pharmacists via the Push Doctor platform.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
It's been quite a year for digital, from Akili's de novo clearance to the downfall of 'digital pill' maker Proteus. MobiHealthNews takes a look back at the highlights.
At a recent online event, Novartis Chief Digital Officer Betrand Bodson gave an update on a digital strategy that began in 2018.